Page 80 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Molecular shift in FLT3 during AML course

doi: 10.4161/cc.5.6.2586 prognosis in the AMLCG study and usefulness as a marker
for the detection of minimal residual disease. Blood.
8. Choudhary C, Müller-Tidow C, Berdel WE, Serve H.
Signal transduction of oncogenic Flt3. Int J Hematol. 2002;100:59-66.
2005;82(2):93-99. doi: 10.1182/blood.v100.1.59
doi: 10.1532/IJH97.05090 18. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and
9. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3- management of AML in adults: 2022 recommendations
activating mutations in 979 patients with acute myelogenous from an international expert panel on behalf of the ELN.
leukemia: Association with FAB subtypes and identification Blood. 2022;140(12):1345-1377.
of subgroups with poor prognosis. Blood. 2002;99:4326-4335. doi: 10.1182/blood.2022016867
doi: 10.1182/blood.v99.12.4326 19. Chen EC, Shimony S, Luskin MR, Stone RM. Biology and
10. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation management of acute myeloid leukemia with mutated
of D835 within the activation loop of FLT3 in human NPM1. Am J Hematol. 2025;100(4):652-665.
hematologic malignancies. Blood. 2001;97:2434-2439. doi: 10.1002/ajh.27600
doi: 10.1182/blood.v97.8.2434 20. Williams AB, Nguyen B, Li L, et al. Mutations of FLT3/ITD
11. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 confer resistance to multiple tyrosine kinase inhibitors.
internal tandem duplication mutations in adult acute Leukemia. 2013;27(1):48-55.
myeloid leukaemia define a high-risk group. Br J Haematol. doi: 10.1038/leu.2012.191
2000;111:190-195.
21. Lam SSY, Leung AYH. Overcoming resistance to FLT3
doi: 10.1046/j.1365-2141.2000.02317.x inhibitors in the treatment of FLT3-mutated AML. Int J Mol
12. Blau O, Berenstein R, Sindram A, Blau IW. Molecular Sci. 2020;21(4):1537.
analysis of different FLT3-ITD mutations in acute myeloid doi: 10.3390/ijms21041537
leukemia. Leuk Lymphoma. 2013;54(1):145-152.
22. Baker SD, Zimmerman EI, Wang YD, et al. Emergence of
doi: 10.3109/10428194.2012.704999 polyclonal FLT3 tyrosine kinase domain mutations during
13. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, sequential therapy with sorafenib and sunitinib in FLT3-
and TP53 mutations in elderly patients with acute myeloid ITD-positive acute myeloid leukemia. Clin Cancer Res.
leukemia. Blood. 2001;97:3589-3595. 2013;19(20):5758-5768.
doi: 10.1182/blood.v97.11.3589 doi: 10.1158/1078-0432.CCR-13-1323
14. Choudhary C, Schwable J, Brandts C, et al. AML-associated 23. Garg M, Nagata Y, Kanojia D, et al. Profiling of somatic
Flt3 kinase domain mutations show signal transduction mutations in acute myeloid leukemia with FLT3‐ITD at
differences compared with Flt3 ITD mutations. Blood. diagnosis and relapse. Blood. 2015;126(22):2491‐2501.
2005;106:265-273. doi: 10.1182/blood‐2015‐05‐646240
doi: 10.1182/blood-2004-07-2942 24. Gupta A, Viswanatha DS, Patnaik MM. FLT3 mutation
15. Campregher PV, Pinto De Mattos VR, Salvino MA, Souza testing in acute myeloid leukemia. JAMA Oncol.
Santos FP, Hamerschlak N. Successful treatment of post- 2017;3(7):991-992.
transplant relapsed acute myeloid leukemia with FLT3 doi: 10.1001/jamaoncol.2017.0257
internal tandem duplication using the combination of
induction chemotherapy, donor lymphocyte infusion, 25. Lin TL, Williams T, He J, et al. Rates of complete diagnostic
sorafenib and azacitidine. Report of three cases. Hematol testing for patients with acute myeloid leukemia. Cancer
Transfus Cell Ther.2020;42(1):89-92. Med. 2015;4:519-522.
16. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic doi: 10.1002/cam4.426
significance of activating FLT3 mutations in younger adults 26. Kottaridis PD, Gale RE, Langabeer SE, Frew ME,
(16 to 60 years) with acute myeloid leukemia and normal Bowen DT, Linch DC. Studies of FLT3 mutations in paired
cytogenetics: A study of the AML study group Ulm. Blood. presentation and relapse samples from patients with
2002;100(13):4372-4380.
acute myeloid leukemia: Implications for the role of FLT3
doi: 10.1182/blood-2002-05-1440 mutations in leukemogenesis, minimal residual disease
detection, and possible therapy with FLT3 inhibitors. Blood.
17. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3
length mutations in 1003 patients with acute myeloid 2002;100(7):2393-2398.
leukemia: Correlation to cytogenetics, FAB subtype, and doi: 10.1182/blood-2002-02-0420

Volume 9 Issue 3 (2025) 72 doi: 10.36922/EJMO025150101